Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Advancements in drug formulations
3.2.1.2 Increasing incidence of chronic diseases
3.2.1.3 Surging investment in research and development
3.2.1.4 Growing prevalence of cancers
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse reactions and side effects associated with prolonged use of Corticosteriods
3.2.2.2 Pricing pressure on the companies by government
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Glucocorticoids
5.3 Mineralocorticoids
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Topical
6.3 Injectable
6.4 Oral
6.5 Inhaled
Chapter 7 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Skin allergies
7.3 Gastroenterology
7.4 Endocrinology
7.5 Acute respiratory diseases
7.6 Rheumatology indications
7.7 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Astellas Pharma Inc.
10.3 AstraZeneca plc
10.4 Bausch Health Companies Inc.
10.5 Bayer AG
10.6 Cipla Limited
10.7 Eli Lilly and Company
10.8 GlaxoSmithKline plc
10.9 Lupin Limited
10.10 Merck & Co., Inc.
10.11 Novartis AG
10.12 Pfizer Inc.
10.13 Sanofi S.A
